Physician profile
Philip Cheng
NPI 1285195602
$1,986.69
in general payments reported to CMS, 2019-2025
11 companies · $511 in 2025
The $511 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $196 · 2023: $899 · 2024: $250 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $697.00 | 2021-2025 | Clareon, Centurion, Argos |
| Bausch & Lomb Americas INC. | $453.59 | 2022-2023 | Stellaris |
| Rxsight INC | $363.17 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sight Sciences, INC. | $164.24 | 2024-2025 | Omni Surgical System |
| Glaukos Corporation | $139.92 | 2023 | |
| Jazz Pharmaceuticals INC. | $67.29 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $28.05 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $21.94 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $20.21 | 2025 | Tecnis Iol |
| Glaxosmithkline, LLC. | $15.98 | 2023 | Nucala |
| Amgen INC. | $15.30 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.